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in the following review, we highlight publications between
une 2009 and May 2010 in the field of non–ST-segment
levation acute coronary syndromes (NSTE-ACS).
isk Factors
working group of the National Heart, Lung, and Blood
nstitute published a Special Report on the current status
nd future directions on the identification of individuals at
igh risk for cardiovascular events (including NSTE-ACS)
ithin 1 year (1). Among the key recommendations was one
irectly applicable to acute coronary syndromes (ACS),
amely, to further our understanding of the pathobiology of
cute cardiovascular events, with attention to the influence
f environmental and biologic factors that account for
ndividual variability.
The Year in Atherothrombosis paper (2) provides an
xcellent update of the pathobiology of ACS; in the follow-
ng, we highlight several publications that identified various
nvironmental and dietary factors associated with an in-
reased risk of developing ACS (Table 1).
Both an abrupt decline in air temperature (3) and poor air
uality (increased exposures to carbon monoxide as is
ypically generated by traffic [4], fine particulate matter [5],
nd cigarette smoke [5]) were reported to trigger ACS.
iet-related issues that increase cardiovascular risk include
igh dietary salt intake (6), lack of moderate alcohol
onsumption (7), and development of the metabolic syn-
rome (8). An analysis in adults not known to be diabetic
ound the glycated hemoglobin to be useful in the recogni-
ion of diabetes and in assessing the risk of cardiovascular
vents (9), which should help to identify high-risk patients
t an earlier time.
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ccepted September 2, 2010.Unfortunately, the adherence to behavioral advice on
iet, exercise, and smoking cessation after ACS is poor (less
han one-third of patients comply with all 3 of these
ecommendations), despite evidence for a “therapeutic ef-
ect” that is similar to or exceeds that of evidence-based
edical therapies (10). In addition, an analysis of 4 U.S.
urveys found that the prevalence of low risk factor burden
nonsmoker, total cholesterol 200 mg/dl without medica-
ion, blood pressure 120/80 mm Hg without medication,
ody mass index 25 kg/m2, no diabetes) is once again
alling after 2 decades of improvement between 1970 and
990 (11).
iomarkers
f 30 biomarkers from different pathophysiologic pathways
valuated in 2 multinational general population cohorts,
-terminal pro-brain natriuretic peptide (BNP), C-reactive
rotein (CRP), and sensitive troponin I had the strongest
ssociations with incident coronary or stroke events at 10
ears (12). Addition of a biomarker score derived from these
markers improved prognostication and resulted in signif-
cant reclassification of individuals into risk categories. A
econd analysis comparing these same 3 markers plus
stimated glomerular filtration rate at the time of random-
zation, 6 weeks, and 6 months after NSTE-ACS revealed
ncremental prognostic value only with N-terminal pro-
NP (13). Whether the lack of independent contribution of
RP and troponin I in this second analysis was due to
ifferences in the populations studied (general population
s. NSTE-ACS), type of event (incident vs. recurrent), or
djustment for estimated glomerular filtration rate in the
odel is not clear. An additional important role for BNP in
he management of patients with NSTE-ACS was reported
n the MERLIN–TIMI 36 (Metabolic Efficiency With
anolazine for Less Ischemia in Non-ST Elevation Acute
oronary–Thrombolysis In Myocardial Infarction 36) trial,
n which an early BNP elevation identified patients who
enefited from treatment with ranolazine (compared with
lacebo), with a hazard ratio (HR) of 0.79 (p  0.009) for
he primary end point of cardiovascular death, myocardial
nfarction (MI), or recurrent ischemia among patients with
BNP 80 pg/ml; whereas no detectable benefit with
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ion p  0.05) (14).
Several studies evaluated newer, more sensitive assays of
roponin I (15,16) and T (17). A comparison of 3 different
ensitive troponin I and 1 troponin T assay demonstrated
igh diagnostic accuracy (area-under-the-curve 0.94 to
.98), indicating that these new assays can substantially
mprove the early diagnosis of MI in patients with rest pain
18). With these ultrasensitive troponin assays, many pa-
ients who heretofore were diagnosed with unstable angina
ill now be reclassified as non–ST-segment elevation MI
19), because even outpatients with ischemia during stress
esting might have detectable release of troponin with
ltrasensitive troponin assays (20).
Two studies of growth-differentiation factor (GDF)-15
emonstrated novel potential applications for this promising
iomarker in patients across the spectrum of coronary heart
rial AcronymsTable 1 Trial Acronyms
Acronym
ABOARD Angioplasty to Blunt the Rise of Troponin in Acute C
ACUITY Acute Catheterization and Urgent Intervention Triag
COGENT Clopidogrel and the Optimization of Gastrointestina
CRUSADE Can Rapid Risk Stratification of Unstable Angina Pa
CURRENT Clopidogrel Optimal Loading Dose Usage to Reduce
GRACE Global Registry of Acute Coronary Events
ISAR-REACT Intracoronary Stenting and Antithrombotic Regimen
L-TAP2 Lipid Treatment Assessment Project 2
MERLIN Metabolic Efficiency With Ranolazine for Less Ische
OASIS Optimal Antiplatelet Strategy for InterventionS
PLATO Platelet Inhibition and Patient Outcomes
ROMICAT Rule Out Myocardial Infarction with Computer Assis
SEPIA Study Program to Evaluate the Prevention of Ischem
STACKENOX STACK-on to ENOXaparin
TIMI Thrombolysis In Myocardial Infarction
TRITON Trial to Assess Improvement in Therapeutic Outcom
CC/AHA  American College of Cardiology/American Heart Association.
pdated Assessment of Novel Cardiovascular BiomarkersTable 2 Updated Assessment of Novel Cardiovascular Biomark
Biomarker (Ref. #) Description/Mechanism
Copeptin (23) C-terminal portion of the vasopressin prohormone
marker of acute endogenous stress
CXCL 16 (24) Interferon-gamma-regulated chemokine and scav
for oxidized LDL
Cystatin C (25) Small nonglycated protein that is freely filtered by
and thus an endogenous marker of glomerular
OxPL/apoB (26) Increased levels of OxPL/apoB are believed to ind
stabilization and early atherosclerosis regressio
Rs1333049 variant on
chromosome 9p21 (27)
Genetic locus associated with plaque formation a
plaque instability and rupture
Soluble Fas (28) Promotes apoptosis after activation by the p53 pr
upregulation in the setting of hypoxia
ST2 (29) A member of the interleukin receptor family, one
acts as a ligand for free interleukin-33, which e
antihypertrophic, antifibrotic, and antiapoptoticCS  acute coronary syndrome(s); BNP  brain natriuretic peptide; LDL  low-density lipoprotein; MI isease (21) and over the long term (through 5 years) after
STE-ACS (22). Furthermore, serial measurements of
DF-15 at 6 weeks and 3 and 6 months after NSTE-ACS
dded incremental prognostic information beyond baseline
evels, with persistently elevated levels 1,800 ng/l associ-
ted with high rates of death (20%) and the composite of
eath or reinfarction (30%) at 5 years (22).
With the introduction of improved assays for the 4 major
ardiovascular biomarkers (troponin, CRP, BNP, GDF-15),
he bar has now been set quite high for future novel makers.
he key findings for a selected number of newer biomarker
andidates (23–29) are summarized in Table 2. However,
ven if newer biomarkers provide only small contributions
o prognostication, they might help us to better understand
he pathophysiology of ACS and help in the selection of
ppropriate therapy (30). For example, a series of inflam-
atory and vasoconstrictive factors were found to be in-
Trial Name
y Syndromes Randomized for an Immediate or Delayed Intervention
egy
s Trial
suppress Adverse outcomes with Early Implementation of the ACC/AHA Guidelines
rent EveNTs
Early Action for Coronary Treatment
Non–ST-Elevation Acute Coronary Syndrome
mography
h direct Anti-Xa inhibition
Optimizing Platelet Inhibition with Prasugrel
Major Finding
a Addition of copeptin levels to troponin T allowed a rapid and
highly accurate rule out of MI
eceptor Levels obtained within 24 h of admission were independently
associated with long-term mortality
omerulus,
on rate
Strong independent predictor for the composite of cardiac death,
MI, and recurrent angina requiring repeat hospital stay
laque Atorvastatin 80 mg increased levels of OxPL/apoB across
cardiovascular disease subgroups and across all subgroups
based on lipoprotein levels
sibly Variant was independently associated with reinfarction and the
composite of cardiac death or MI
nd Levels were strongly and independently associated with a
discharge diagnosis of ACS, rose sooner than troponin, and
improved the diagnostic accuracy in suspected cases of ACS
f ST2
s
Levels peak 6 to 17 h after symptom onset and predicted 1-yr
mortality independent of clinical factors (but not after
adjustment for N-terminal pro-BNP)oronar
e Strat
l Event
tients
Recur
: Rapid
mia in
ted To
ia wit
es byers
that is
enger r
the gl
filtrati
icate p
n
nd pos
otein a
form o
xerts
effectmyocardial infarction; OxPL/apoB  Oxidized phospholipids on apolipoprotein B.
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Year in NSTE-ACS December 14/21, 2010:2126–38reased in emotional, stress-induced ACS in patients after
he World Cup soccer games in 2006 (31). It will be
nteresting to learn whether these observations are con-
rmed and extended in similar analyses from the World
up 2010 games.
maging
uring the past year, important contributions were made in
urthering 3 goals of cardiac imaging in patients with or
uspected to have NSTE-ACS: 1) identification of unstable
laques at high-risk of rupture; 2) diagnosis of ACS in
atients with equivocal signs and symptoms; and 3) simul-
aneous evaluation of other potentially life-threatening con-
itions in the differential diagnosis of acute chest pain.
In a large (n  6,814) multiethnic population-based
ohort of individuals 45 to 84 years of age, without known
ardiovascular disease, followed for a median of 5.8 years,
oronary artery calcium scoring substantially improved risk
ssessment (36% of patients were reclassified more accu-
ately) when added to models based on traditional risk
actors, medication use, and lipid levels (32). More detailed
nalysis of plaque morphology identified 2 characteristics—
ositive vessel remodeling and low-attenuation plaques
Fig. 1)—that were associated with plaque rupture and ACS
mong 1,059 patients who were followed for clinical events
or an average of 27 months after imaging (33). Several
ovel therapies targeted inflammatory pathways that con-
ribute to such vulnerable low-attenuation plaques, includ-
Figure 1 Angiographic Characteristics of a High-Risk Plaque in
(A) Curved multiplanar reformation images of the left anterior descending artery (LAD)
low-attenuation plaque, and spotty calcification were detected in the LAD on computed
computed tomography angiography involving the high-risk plaque seen earlier in the LAng inhibitors of 5-lipoxygenase (34) and lipoprotein-
ssociated phospholipase A2 (35), both candidates for
odifying the atherosclerotic process. Decreasing the lipid
ontent in plaques might also improve outcomes after
ercutaneous coronary intervention (PCI), because such
esions have a higher rate of no-reflow after successful
oronary stenting (36).
The ROMICAT (Rule Out Myocardial Infarction with
omputer Assisted Tomography) trial demonstrated the
ncremental diagnostic value of left ventricular function
LVF), as assessed by computed tomography, in patients
ith an inconclusive evaluation for ACS in the emergency
epartment (37). The diagnostic accuracy of regional LVF
n the detection of ACS had sensitivities and specificities of
9% and 86%, respectively, among patients with significant
tenosis, whereas they were 60% and 86% in those without
vident high-grade stenosis. In the overall population, the
ddition of regional LVF increased the sensitivity to detect
CS by cardiac computed tomography by 10% (from 77%
o 87%) compared with coronary assessment alone.
nticoagulants
everal new trials, as well as secondary analyses from prior
tudies, provided additional insight regarding each of the 4
urrently recommended parenteral anticoagulants in
STE-ACS (unfractionated heparin [UFH], enoxaparin,
ivalirudin, and fondaparinux). In the STACKENOX
STACK-on to ENOXaparin) trial (38), the addition of 70
tient 6 Months Before ACS
ircumflex artery (LCX), and right coronary artery (RCA). (B) Positive remodeling,
graphy angiography. (C) Acute coronary syndrome (ACS) occurred 6 months after
tical arrow). Reproduced, with permission, from Motoyama et al. (33).a Pa
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December 14/21, 2010:2126–38 Year in NSTE-ACS/kg of UFH 4 to 10 h after the last dose of enoxaparin 1
g/kg resulted in supratherapeutic anti-Xa and anti-IIa
evels and complete inhibition of thrombin generation for
2 h, despite an activated clotting time that was 270 s.
his addition increased the risk of peri- and post-procedural
leeding. Therefore, to avoid excess bleeding, UFH should
ot be administered routinely in the catheterization labora-
ory 10 h after administration of 1 mg/kg enoxaparin,
nless factor Xa activity levels are low.
An analysis of the level of anticoagulation achieved in a
ubset of patients from the OASIS-5 (Fifth Organization to
ssess Strategies in Ischemic Syndromes) trial found that
.5 mg daily of the indirect factor Xa inhibitor fondapa-
inux, when compared with enoxaparin 1 mg/kg twice daily,
aused less bleeding while providing similar efficacy.
ondaparinux achieved significantly lower intensity and less
ariability of anticoagulation than enoxaparin (39). In the
ame trial, reduced bleeding rates with fondaparinux also
ere observed in the subgroups of patients receiving a
oncomitant glycoprotein IIb/IIIa inhibitor (GPI) or thien-
pyridine, 2 potent antiplatelet classes that increase the risk
f bleeding (40).
These findings have important implications for both
linical practice and the interpretation of bleeding in clinical
tudies involving anticoagulants targeting clotting factors
hat are more proximal than thrombin in the coagulation
ascade. To ensure therapeutic levels of anticoagulation in the
atheterization laboratory and in patients who might need
onstandard dosing of enoxaparin (e.g., patients with marked
besity, severe renal failure, or who are not at steady-state), a
apid and reliable bedside assessment of anti-Xa activity (41)
epresents a high priority for development.
Further analyses of the ACUITY (Acute Catheterization
nd Urgent Intervention Triage strategY) trial compared
arious antithrombotic strategies in patients with NSTE-
CS in 2 important subgroups of patients, namely those
anaged without revascularization (42) and patients with
hronic kidney disease (43). Large and consistent reductions
n bleeding complications with bivalirudin monotherapy
ompared with heparin with a GPI, without loss of ischemic
rotection through 1 year, were reported. In the ISAR-
EACT (Intracoronary Stenting and Antithrombotic Reg-
men: Rapid Early Action for Coronary Treatment) 3 trial
44), bivalirudin was compared with UFH (140 U/kg, a
ose in excess of current guideline recommendations and
hat used in the ACUITY trial) in 4,570 patients with stable
r unstable angina and normal levels of troponin T and
reatine kinase myocardial band who underwent PCI. Pa-
ients randomized to bivalirudin experienced less bleeding
nd had similar rates of ischemic complications through 1
ear compared with those who received UFH. Of note, in
his trial all patients were pre-treated with clopidogrel 600
g more than 2 h before PCI, and no GPI was used.
The observations that less intensive anticoagulation with
ither bivalirudin or fondaparinux (which has not been
pproved for use in ACS by the U.S. Food and Drug sdministration at the time of this writing) is associated with
educed bleeding and preservation of ischemic protection,
akes these 2 anticoagulants attractive alternative choices in
atients with NSTE-ACS, especially in patients at in-
reased risk of bleeding.
Novel anticoagulants, particularly agents that inhibit a
ore proximal target in the coagulation cascade, continue to
e developed with the hope of improving safety while
chieving similar or better efficacy than current therapies.
he direct factor Xa inhibitor, otamixaban, at intravenous
nfusions of 0.105 to 0.140 mg/kg/h, showed promise in
educing ischemic complications while achieving a similar
afety profile compared with UFH plus eptifibatide in the
ose-ranging SEPIA-ACS1–TIMI 42 (Study Program to
valuate the Prevention of Ischemia with direct Anti-Xa
nhibition-Acute Coronary Syndromes-1-ST Elevation
cute Coronary–Thrombolysis In Myocardial Infarction
2) trial (45). The oral factor Xa inhibitor rivaroxaban is
urrently being evaluated in a large phase III clinical trial in
ddition to standard antiplatelet agents in patients after
CS (46). A factor XIIa inhibitor, recombinant human
lbumin infestin-4, was shown to prolong the activated
artial thromboplastin time in vitro with human plasma and
o abolish occlusive arterial thrombus formation in animal
odels (47). This anticoagulant might prove to be an
ffective yet safer alternative to currently available antico-
gulants, because the factor XII-induced coagulation path-
ay is essential for pathologic thrombosis but is dispensable
or hemostasis. M118, a “designed” low-molecular-weight
eparin that is a potent inhibitor of both factors Xa and IIa,
as predictable pharmacokinetics after subcutaneous or
ntravenous administration, can be assessed by bedside
oagulation assays, and is reversible with protamine is being
eveloped for use in PCI and ACS (48). Similarly, studies
ith RB006 (a ribonucleic acid aptamer with high affinity
nd specificity for factor IXa) and RB007, its aptamer/
ntidote, are ongoing or planned in patients who have
ndergone PCI or coronary artery bypass grafting (CABG)
nd in patients with ACS at high risk of bleeding (49).
ntiplatelet Agents
ey changes in recommendations related to antiplatelet
herapy from the American College of Cardiology/
merican Heart Association/Society for Coronary Angiog-
aphy and Intervention 2009 Focus Guideline Update on
CI (50) are summarized in Table 3, including new
ecommendations regarding the use of prasugrel and the
uration of dual antiplatelet therapy after stenting.
Ticagrelor—an oral, reversible P2Y12 receptor antagonist—
chieves greater platelet inhibition than clopidogrel, with a
aster onset and offset (51), and is not limited by nonre-
ponsiveness (52), as has been described with clopidogrel. In
he PLATO (Platelet Inhibition and Patient Outcomes)
rial of 18,624 patients with ACS (including both ST-
egment elevation MI and NSTE-ACS) treated with aspi-
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Year in NSTE-ACS December 14/21, 2010:2126–38in, in which ticagrelor was compared with clopidogrel, this
ew P2Y12 inhibitor reduced the rate of cardiovascular
eath, MI, or stroke by 16% (p  0.001) compared with
lopidogrel (Fig. 2) (53). Although total major bleeding was
imilar between ticagrelor and clopidogrel (HR: 1.04, p 
.43), non–CABG-related major bleeding was increased by
9% (p  0.03) in patients randomized to ticagrelor (Fig. 2).
mpressively, all-cause mortality through 12 months was re-
uced with ticagrelor (4.5%, vs. 5.9% with clopidogrel;
ajor Updates From the 2009 ACC/AHA/SCAI PCI Guideline UpdaTable 3 Major Updates From the 2009 ACC/AHA/SCAI PCI Gu
New Recommendation
Class I
1. Thienopyridine therapy after stenting—after placement of a BMS or DES during
prasugrel 10 mg daily should be given for at least 12 months (LOE: B).
2. In patients in whom CABG is planned and can be delayed, prasugrel should be
surgery to allow for dissipation of the antiplatelet effect (LOE: C).
3. Patients with definite or likely NSTE-ACS selected for an invasive approach sho
(LOE: A) or prasugrel at the time of PCI (LOE: B) as the second antiplatelet age
4. In patients with chronic kidney disease undergoing angiography who are not un
isosmolar contrast medium (LOE: A) or a low-molecular-weight contrast medium
indicated (LOE: B).
Class IIa
1. It is reasonable for initially stabilized high-risk patients with GRACE risk score 
within 12 to 24 h of admission. For patients not at high risk, an early invasive a
Class IIb
1. Continuation of clopidogrel or prasugrel beyond 15 months might be considere
(LOE: C)
2. PCI of the left main coronary artery with stents as an alternative to CABG migh
conditions that are associated with a low risk of PCI-related procedural complic
an increased risk of adverse surgical outcomes (LOE: B)
rom Kushner et al. (50).
ACC/AHA  American College of Cardiology/American Heart Association/Society for Coronary
oronary artery bypass grafting; DES drug-eluting stent(s); GRACE Global Registry of Acute Cor
ntervention.
Figure 2 Main Findings of the PLATO Trial
The rates of the primary composite (cardiovascular death, myocardial infarc-
tion, or stroke) and all-cause mortality were significantly reduced by ticagrelor
(53). Excluding coronary artery bypass graft (CABG)-related bleeding events, an
excess of 7 major bleeding events/1,000 patients treated occurred with
ticagrelor. HR  hazard ratio; PLATO  Platelet Inhibition and Patient
Outcomes.c 0.001)—a finding that had not been observed with oral
ntiplatelet agents other than aspirin (when compared with
lacebo). In the 11,074 patients enrolled in the PLATO trial
ith a qualifying NSTE-ACS, ticagrelor reduced the primary
nd point by 17%, from 12.3% to 10.1% (HR: 0.83; 95%
onfidence interval: 0.74 to 0.93). Among 13,408 patients
ndergoing a planned invasive strategy in the PLATO trial,
icagrelor was associated with a 16% reduction in the compos-
te primary end point (9.0% vs. 10.7%, p 0.0025), similar to
hat observed in the entire trial population (54).
On March 12, 2010, the U.S. Food and Drug Adminis-
ration added a boxed warning to the clopidogrel label to
aution that poor metabolizers of the drug might not receive
ts full benefits (55). However, although the cytochrome
450 2C19 genotype is associated with the antiplatelet
ffect and clinical efficacy of clopidogrel (56) and kits to
dentify this genotype are now commercially available (57),
here are many other variables (e.g., patient age [58],
ematocrit and erythrocyte deformability [59], use of GPIs
60]) that influence the response of an individual to clopi-
ogrel. Gene variability can explain only 11.5% of the
ariation in the antiplatelet response to clopidogrel (61),
ven after controlling for standard patient characteristics.
hus, the value of genotyping patients to identify those who
ight be hyporesponders to clopidogrel remains uncertain.
nstead, reliable and portable devices to directly measure the
ntiplatelet effect of clopidogrel are likely to prove more
seful in the identification of patients at higher risk of
ubsequent thrombotic events, such as early stent thrombosis
62,63).
Another factor that might reduce the antiplatelet effect of
e Update
Change Compared With 2007
r ACS, clopidogrel 75 mg or Duration after BMS extended to 12 months;
added prasugrel
tinued at least 7 days before Added prasugrel (no change to 5-day period
for clopidogrel)
eive dual-antiplatelet therapy New recommendation
ng chronic dialysis, either an
r than ioxaglate or iohexol is
New recommendation regarding low-
molecular-weight contrast mediums
o undergo an early invasive strategy
ch is also reasonable (LOE: B).
New recommendation
tients undergoing DES placement Modifications in italics
nsidered in patients with anatomic
and clinical conditions that predict
New recommendation
raphy and Intervention; ACS  acute coronary syndrome; BMS  bare-metal stent(s); CABG 
vents; LOE Level of Evidence; NSTE non–ST-segment elevation; PCI percutaneous coronaryteidelin
PCI fo
discon
uld rec
nt.
dergoi
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Angioglopidogrel and hence increase stent thrombosis and other
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December 14/21, 2010:2126–38 Year in NSTE-ACSschemic complications is a pharmacodynamic interaction
competitive binding of CYP2C19) (64) between clopi-
ogrel and proton pump inhibitors (PPIs), in particular
meprazole (65). However, the clinical impact of this
harmacodynamic interaction remains controversial. Several
tudies have shown no increased risk in ischemic events
66,67) with concomitant use of PPIs and clopidogrel,
hereas gastrointestinal bleeding was reduced (67). A met-
nalysis of 23 studies in 93,278 patients demonstrated
ubstantial heterogeneity in the effect on cardiovascular
vents, with observational studies demonstrating an increase
n major adverse cardiovascular events (68). In contrast,
igher-quality studies (propensity-matched, subgroup anal-
ses from randomized trials) showed no added risk. Indeed,
esults from the only large prospectively randomized trial
COGENT [Clopidogrel and the Optimization of Gastro-
ntestinal Events Trial]) indicated no increase in cardiovas-
ular events but a protective effect on gastrointestinal
omplications among patients taking clopidogrel who were
ssigned omeprazole compared with placebo (69). Further-
ore, not all PPIs are metabolized by CYP2C19 to the
ame extent, and some PPIs—such as pantoprazole—
ave a much weaker effect on the antiplatelet effect of
lopidogrel (70). Finally, a breath test that was recently
eveloped to predict CYP2C19 phenotype might be useful
n the identification of patients who are low-responders to
lopidogrel (71).
Controversy over the optimal duration of clopidogrel
reatment after coronary stent placement continues. An
nalysis of 2,017 patients with ACS from an integrated
ealth care delivery system demonstrated a clustering of
eath or MI in the first 90 days after stopping clopidogrel
72), whereas 2 randomized trials conducted in a total 2,701
atients in Korea showed no benefit of continuing clopi-
ogrel beyond 12 months (73).
Higher-dose regimens of clopidogrel have continued to
ain traction in clinical practice, although convincing evi-
ence from large prospective randomized trials is lacking.
he CURRENT (Clopidogrel Optimal Loading Dose
sage to Reduce Recurrent EveNTs)–OASIS 7 trial (74)
as a 2  2 factorial study of high-dose (600 mg load
ollowed by 150 mg daily for 1 week, then 75 mg daily)
ersus standard-dose clopidogrel (300 mg load, 75 mg
aintenance) and high- (300 to 325 mg) versus low-dose
81 to 100 mg) aspirin in 25,086 patients with unstable
ngina or acute MI who were scheduled to undergo angiog-
aphy within 72 h of hospital arrival. There was no statistical
ifference in the outcome between high- and standard-dose
lopidogrel in the primary composite of cardiovascular death
nd MI. However, there was evidence for heterogeneity
ependent on the aspirin stratum (patients taking high-dose
spirin did better with high-dose clopidogrel than with
tandard-dose clopidogrel), and there was evidence of a
eduction in ischemic events and stent thrombosis among
he patients who were randomized to high-dose clopidogrel
nd who underwent PCI. “Additional analyses from the TRITON–TIMI 38 trial
Trial to Assess Improvement in Therapeutic Outcomes
y Optimizing Platelet Inhibition With Prasugrel–
hrombolysis In Myocardial Infarction 38) (75), a study of
3,608 patients with moderate-to-high-risk ACS scheduled
o undergo PCI, provided further insight regarding the
omparative efficacy of the third-generation thienopyridine
rasugrel versus clopidogrel. A pharmacodynamic substudy
emonstrated greater antiplatelet effects with prasugrel
both after the loading dose and with maintenance dosing)
nd less hyporesponsiveness at 1 to 2 h after loading with
rasugrel compared with clopidogrel (27% vs. 75%, p 
.039) (75). Also, prasugrel reduced overall MIs as well as
arious subtypes of MI, including spontaneous or peri-
rocedural, large (10 elevation in peak biomarker) or
mall, and early or late (30 days after ACS) (76). The
enefits of prasugrel were present whether adjunctive GPI
as administered or not (77). In a cost-effectiveness analy-
is, total costs were on average $221 lower/patient with
rasugrel compared with brand-name clopidogrel, due to
ewer repeat hospital stays and repeat PCIs (78). Prasugrel
emained an economically attractive treatment option, even
ssuming the availability of a generic clopidogrel costing
1/day, with an incremental cost-effectiveness ratio of
9,727/life-year gained.
Other novel approaches to inhibit platelet activation/
ggregation include the use of intracoronary eptifibatide
uring PCI (which results in higher local glycoprotein
eceptor occupancy and improved microvascular perfusion)
79), administration of the intravenous nonthienopyridine
denosine triphosphate analogue cangrelor (which did not
eet its primary end point of death, MI, or ischemia-driven
evascularization at 48 h in 2 large trials) (80,81), and
nhibition of other platelet receptors (e.g., receptor for
hrombin). The rationale for developing additional potent
ntithrombotic drugs was underscored by an analysis that
emonstrated a 5-fold increase in death or MI in patients
ith NSTE-ACS who were treated with contemporary
ntensive antithrombotic regimens who had ischemia on
ontinuous electrocardiographic monitoring in the first 48 h
fter PCI compared with those who did not (82).
Vorapaxar is a reversible, long-acting, oral inhibitor of the
rotease-activated receptor 1, the main platelet receptor for
hrombin. Phase III clinical trials in patients with ACS (83)
nd secondary prevention in patients with a history of
therosclerotic disease (84) are ongoing. DZ-697b is a new
ral inhibitor of collagen and ristocetin-mediated platelet
ctivation that does not require generation of an active
etabolite (unlike clopidogrel). On the basis of pre-clinical
tudies, it might be as safe (if not safer) than aspirin. In a
hase I study of healthy volunteers, DZ-697b demonstrated
imilar or greater antiplatelet effect compared with 300 mg
lopidogrel (85). It will be interesting to follow the devel-
pment of these promising drugs, which could become
game changers” in the management of patients with ACS.
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major challenge to the analysis of bleeding results from
he multiple definitions of bleeding used across studies that
nclude criteria of varying levels of severity (86,87) and
alidity (88). Academic and regulatory groups have begun to
ddress this “Tower of Babel” by providing recommenda-
ions for collection and reporting of bleeding complications
n clinical trials (89). Such a standardized approach would
llow for more valid cross-study comparisons of various
ypes of bleeding outcomes.
A second challenge to research on bleeding is presented
y the temptation to perform analyses exploring the rela-
ionship between 2 different but related post-randomization
vents, such as bleeding and mortality (90)—analyses that
re highly prone to bias and confounding. These analyses
outcome–outcome analyses) too often do not address the
ey question, “Was the bleeding responsible for the death,
r was bleeding a surrogate marker of a high-risk condition
uch as a malignancy that was responsible for a fatal
utcome?” More sophisticated methods, such as those
ocused on individual patient risk assessment of bleeding
nd ischemic events (91), might provide more reliable and
ess confounded conclusions than simple comparisons of the
ortality rates in patients who had a bleeding event versus
hose who did not.
Patients who receive dual antiplatelet therapy and an oral
nticoagulant (e.g., recently stented patients with atrial
brillation who are at moderate to high risk of stroke), are
t high risk for bleeding of sufficient severity to require
ospital stay (12% annual rate in a Danish registry) (92). A
uropean Society of Cardiology working group published a
onsensus document (93) that provided recommendations
o reduce the risk of bleeding in patients with atrial
brillation presenting with ACS and/or who require PCI,
ncluding the use of radial arterial access (94), safer antico-
gulants (e.g., bivalirudin, fondaparinux), and more fre-
uent use (when appropriate) of bare-metal stents to reduce
he required duration of dual antiplatelet therapy. Use of
emoral vascular closure devices (95) and a computerized
lgorithm to ensure proper dosing of antithrombotics (96)
ave also been associated with a reduction in bleeding in
atients who are at increased risk (e.g., elderly patients and
atients with renal insufficiency).
Gastrointestinal bleeding in patients after ACS has
ained attention, in light of its association with mortality
nd ischemic complications (97). Some of the increased risk
ight be attributed paradoxically to increased thrombosis
aused by the interruption of antiplatelet therapy after
leeding. However, maintenance of a low-level of antiplate-
et therapy for a few weeks, until more intensive antiplatelet
herapy can be resumed safely, might be a reasonable
ompromise. Among patients with cardiovascular disease
nd bleeding from a peptic ulcer, continuation of aspirin 80
g daily was associated with a significant reduction in
ll-cause mortality compared with placebo, although the pate of recurrent ulcer bleeding was double that of patients
aking placebo (98). In patients undergoing elective endo-
copic gastrointestinal procedures, including polypectomy
99), continuation of dual antiplatelet therapy is associated
ith a modest increase risk in bleeding and might reduce
he risk of stent thrombosis and other ischemic complica-
ions (100).
nvasive Therapeutic Strategy
ey changes in the 2009 Focused Update of the American
ollege of Cardiology/American Heart Association/Society
or Coronary Angiography and Intervention Guidelines on
ercutaneous Coronary Intervention that relate to patients
ith NSTE-ACS (50) are summarized in Table 3. Because
his area is covered in detail in another Year in Review series
101), here we briefly summarize selected highlights from
he past year.
Long-term outcomes of a routine invasive strategy com-
ared favorably to a selective invasive approach in a meta-
nalysis of 3 recent trials of patients with NSTE-ACS (102)
ith a 19% (p 0.002) reduction in cardiovascular death or
I over 5 years (Fig. 3). However, the benefit in women
eems to be more uncertain (103), perhaps related to the
resence of less severe obstructive coronary disease on
verage (104,105).
The optimal timing of angiography and revascularization
fter NSTE-ACS remains controversial. Some investigators
ave reported worse myocardial function (106) and higher
ortality (107) with longer delays to PCI, although the
BOARD (Angioplasty to Blunt the Rise of Troponin in
cute Coronary Syndromes Randomized for an Immediate
r Delayed Intervention) trial showed no difference in peak
roponin or clinical ischemic composite in 352 patients
andomized to immediate versus delayed (an average 21 h)
ntervention (108). Also, adjusted short-term mortality was
ncreased when nonemergent CABG was performed early
days 2 to 7) compared with late (days 15 to 60) after
STE-ACS in an observational analysis from Alberta, Can-
da (109). Thus, the optimal timing of PCI and CABG in
table patients after NSTE-ACS is not clear and might differ
ubstantially between the 2 modes of revascularization.
Paradoxically, several studies have reported that patients
ho are less likely to have coronary artery disease (110) or
ho are at lower risk for ischemic events (111) are more
ikely to undergo coronary angiography than higher-risk
atients. In part, this might be due to the parallel increase in
oth ischemic risk and procedural complications that coexist
n older patients (112), in patients with renal failure (113),
nd in those with multiple comorbidities. Advances in renal
rotection, including adequate hydration, use of less neph-
otoxic and lower volumes of contrast media (114), and the
ore frequent use of transradial access (115) or femoral
rterial closure devices (95), should allow these higher-risk
atients to undergo catheterization more safely.
LD
i
a
c
d
i
c
m
r
g
P
t
(
w
b
e
p
s
s
a
t
i
a
o
y
p
(
p
(
p
e
a
t
a
“
t
f
Q
W
p
e
s
g
w
c
d
l
d
e
r
p
(
f
2133JACC Vol. 56, No. 25, 2010 Giugliano and Braunwald
December 14/21, 2010:2126–38 Year in NSTE-ACSipid Management
ata have continued to accrue supporting the benefit of
ntensive statin therapy after ACS. The newest statin
pproved for clinical use, pitavastatin, at a dose of 4 mg/day,
aused regression of coronary plaque volume to a similar
egree as atorvastatin 20 mg/day (116). In patients not
ntensively treated with a prior statin, the regression of
oronary atherosclerosis is rapid, occurring within the first 2
onths of therapy (117). Patients who achieve the largest
eduction in low-density lipoprotein (LDL) experience the
reatest clinical benefit, regardless of age (118).
Several investigations in patients with ACS undergoing
CI demonstrated the benefit of high-dose statin adminis-
ered before PCI both in short-term (119) and intermediate
average 11 months) follow-up (120) as well as when they
ere administered within 10 days after PCI (121). The
enefit was independent of LDL lowering and only partially
xplained by reduction in CRP (121), suggesting that other
leiotropic effects of statin might be important in this
etting. Additional studies of intensive lipid lowering with
tatins in patients with ACS, targeting LDLs 70 mg/dl,
re ongoing (122,123). No adverse effects have been iden-
ified with low achieved LDLs, even among patients receiv-
ng rosuvastatin 40 mg daily for 2 years who achieved an
verage LDL of 61 mg/dl (124).
Raising high-density lipoprotein (HDL) is a second area
f intensive investigation in lipidology. Stimulated by anal-
ses showing that HDL levels add prognostic value to the
Figure 3 Outcomes at 5-Years Comparing Routine Versus Selec
Hazard ratio (HR) and 95% confidence intervals are plotted. The percentages repre
CV  cardiovascular; NF MI  nonfatal myocardial infarction. Adapted, with permisrediction of in-hospital recurrent events after NSTE-ACS g125), trials evaluating very potent cholesterol ester transfer
rotein inhibitors that raise HDL by 25% (dalcetrapib)
126) to 130% (anacetrapib) (127) are ongoing or in the
lanning stage. Both of these second-generation cholesterol
ster transfer protein inhibitors differ from torcetrapib (the
gent that increased mortality in a phase III trial) (128) in
hat neither raises blood pressure nor stimulates the renin-
ngiotensin-aldosterone activity in phase II trials. This
off-target” effect of torcetrapib is hypothesized to explain
he increase in mortality that led to the discontinuation of
urther clinical development of torcetrapib.
uality
ith the concepts of evidence-based care and associated
erformance measures in patients with NSTE-ACS firmly
ntrenched in clinical practice (129), the focus is now
hifting to more challenging subgroups of patients in whom
uideline-based therapies are followed less frequently (e.g.,
omen, elderly patients, patients with chronic kidney or
erebrovascular disease). Although several surveys have
emonstrated improvement in overall adherence to guide-
ines over time (130,131) and many individual recommen-
ations have been incorporated, challenges remain. For
xample, lipid-lowering therapy in high-risk patients di-
ected to achieve guideline-specified LDL goals has im-
roved from 18% a decade ago to 67% in the L-TAP2
Lipid Treatment Assessment Project 2) registry (132), but
ully one-third of patients still do not achieve their LDL
Invasive Strategies From a Meta-Analysis of 3 Trials
he Kaplan-Meier percentages at 5 years.
from Fox et al. (102).tive
sent t
sion,oal, and 70% do not achieve the optional LDL goal of70
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Year in NSTE-ACS December 14/21, 2010:2126–38g/dl. Furthermore, some recommendations, such as refer-
al for cardiac rehabilitation (only 56% of patients were
eferred in a large U.S. survey) (133), continue to lag behind
ther more widely adopted recommendations and deserve
reater attention moving forward.
Ensuring access, proper dosing, and compliance with
herapy were also prominent themes during the past year.
or example, delays in filling a prescription for clopidogrel
fter placement of a drug-eluting stent are common, occur-
ing in 1 of 6 patients, and are associated with adverse
utcomes (134). Even when patients do fill their prescrip-
ions, issues such as medication errors (135), failure to
ptitrate to the desired effect (e.g., beta-blockers to a heart
ate of 50 to 60 beats/min) (136), and premature discon-
inuation of evidence-based medicines (present in one-third
f patients within 3 months of ACS) (137) represent
dditional challenges to delivering optimal care.
Nonadherence to medications is a complex and often
ultifactorial issue (Fig. 4) (138) that is associated with
oth adverse outcomes and higher costs of care (139). Novel
pproaches, such as the application of a systematic standard-
zed collection of information on drug exposure directly
rom patients (140) and pharmacist-based interventions
argeting patients with low literacy in cardiovascular disease
141), are promising tools that might help physicians
mprove medication adherence.
The ultimate goal is ideal cardiovascular health—defined
y the presence of both ideal health behaviors and ideal
Figure 4 Barriers to Patient Compliance With Medications
Major challenges that reduce patient compliance with the prescribed medical regim
socioeconomic issues, and lack of patient motivation. Reproduced, with permissioealth factors (142). The American Heart Association hasommitted itself to achieving the following goals: “By 2020,
o improve the cardiovascular health of all Americans by
0% while reducing deaths from cardiovascular disease and
troke by 20%” (142). To achieve these laudable goals,
ontinued progress in basic research and development of
ffective new drugs and interventions in ACS will be
equired.
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